2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow alpha-Thalassemia: new trials by email Literature Review of alpha-Thalassemia trials Research Report on alpha-Thalassemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia Luspatercept, Placebo - Anemia | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 189 | 2022-12-09 | 2026-09-10 |
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Enriched Hematopoetic Stem Cell Infusion - Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies | Phase 1 / Phase 2 | Withdrawn | Talaris Therapeutics Inc. | 2011-05-01 | 2023-03-03 | |
| Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study deferasirox, placebo - Non-transfusion Dependent Thalassemia | Phase 2 | Completed | Novartis Pharmaceuticals | 166 | 2008-11-01 | 2013-07-09 |
Thalassemia (3) · beta-Thalassemia (3) · Anemia (2) · Anemia, Sickle Cell (2) · Anemia, Diamond-Blackfan (1) · Anemia, Hemolytic (1) · Bone Marrow Failure Disorders (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemoglobinopathies (1) · Hemolysis (1) · Iron Overload (1) · Sickle Cell Trait (1) · Vaso-Occlusive Crises (1)
Anemia, Hemolytic, Congenital (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Hemic and Lymphatic Diseases (4) · Anemia, Hemolytic (3) · Genetic Diseases, Inborn (3) · Hematologic Diseases (3) · Hemoglobinopathies (3) · Anemia (2) · Anemia, Aplastic (1) · Anemia, Hypoplastic, Congenital (1) · Bone Marrow Diseases (1) · Congenital Bone Marrow Failure Syndromes (1) · Iron Metabolism Disorders (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Deferasirox (1) · luspatercept (1)
Bristol-Myers Squibb (1) · Forma Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1) · Talaris Therapeutics Inc. (1)
Italy (3) · United States (3) · Greece (2) · Lebanon (2) · Malaysia (2) · Taiwan (2) · Thailand (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Canada (1) · China (1) · Egypt (1) · Hong Kong (1) · Saudi Arabia (1) · Singapore (1)